Pneumococcal vaccination coverages by age, sex and specific underlying risk conditions among middle-aged and older adults in Catalonia, Spain, 2017

Background: Recent published data on pneumococcal vaccination coverages among adults are scarce. Aim: To update on pneumococcal vaccination uptakes among middle-aged and older adults in Catalonia. Methods: We conducted a population-based retrospective observational study including 2,057,656 individuals >= 50 years old assigned to primary care centres managed by the Catalonian Health Institute on January 2017 (date of data collection). An institutional clinical research database (SIDIAP) was used to classify persons by vaccination status for both 23-valent pneumococcal polysaccharide (PPsV23) and 13-valent pneumococcal conjugate (PCV13) vaccines, as well as to identify underlying risk conditions. Results: Overall, 796,879 individuals (38.7%) had received PPsV23 and 13,607 (0.7%) PCV13. PPsV23 coverage increased with age: 9.2% (95,409/1,039,872) in 50-64 year olds, 63. 1 %(434,4 08 / 688 ,7 86 ) in 65-79 year olds and 81.2% (267,062/328,998) in >= 80 year olds (p<0.001). PCV13 coverage also increased with age, although percentages were smaller in all age strata (4,250/10339,872: 0.4%; 6,005/688,786: 0.9% and 3,352/328,998:1.0%, respectively; p < 0.001). By sex, no substantial coverage differences were observed. Considering publicatty funded target groups for PPsV23 vaccination in Catalonia (i.e. (65 < year olds with at least one risk factor, plus all adults aged >= 65 years), PPsV23 coverage reached 52.8% (771,722/1,462,261) in our study population. Regarding PCV13 publicly funded targets (i.e. all-age immunocom promised persons), PCV13 coverage was 3.3% (6,617/202,348). By risk conditions, the highest PPsV23 coverage appeared in congestive heart failure (51,909/63,596; 81.6%), chronic renal disease (122,79058,726;77.4%) and chronic bronchitis/emphysema (96,453/132,306; 72.9%). Maximum PCV13 coverage appeared in cirrhosis (294/7,957;3.7%), chronic renal disease (5,633/158,726;3.5%) and chronic bronchitis/emphysema (2,859/132,306;2.2%). Conclusion: Pneumococcal vaccination coverages in Catalonian adults are suboptimal, especially for PCV13.